trial

Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects

NCTId NCT00743405
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 30 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2008-12-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Single
Start
2008-05-02
Primary completion
2008-12-15
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
GSK1034702

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1
Primary Completion Date
2008-12-15
Status
COMPLETED
relationships
The graph out of here
drug
GSK1034702
drug
lead_sponsor
GlaxoSmithKline
company
indication
Cognitive Disorders
indication
Schizophrenia
indication
Cognitive Dysfunction
indication